<DOC>
	<DOC>NCT01245556</DOC>
	<brief_summary>The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with ipilimumab; and then to evaluate the anti-tumor response to BMS-908662 when administered in combination with ipilimumab.</brief_summary>
	<brief_title>Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion: Male and female subjects ≥ 18 years of age with a histologic or cytologic diagnosis of Stage III or Stage IV (unresectable) melanoma Enrollment to cohort expansion will be limited to only those subjects whose tumors demonstrate the BRaf V600E mutation ECOG ≤ 1 Adequate organ &amp; marrow function Exclusion: Uncontrolled or significant cardiovascular disease Cohort expansion: Prior therapy with a RAF inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>